Articles From: German Econ Min Wants Future Government to Rule on Airbus Loan Payment to REPEAT-BMO Insurance Study: More than Two-thirds of Canadian Women are Concerned about the Financial Costs of Cancer


BERLIN--Germany's Economics Ministry said Sunday it's up to the next government to determine the conditions on payment of the roughly EUR600 million ($828.2 million) final loan tranche to aircraft maker Airbus for construction of the new A350 model.
Sign-up for German Econ Min Wants Future Government to Rule on Airbus Loan Payment investment picks
2013/10/27
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the discovery of a novel and potentially clinically actionable oncogenic gene fusion in lung cancer, NTRK1 , using FoundationOne™, was published in the current online edition of Nature Medicine 1 .
Sign-up for Foundation Medicine Identifies Novel, Clinically Actionable Gene Fusion NTRK1 in Lung Cancer; Data Published in Nature Medicine investment picks
Goody’s®, the brand known for its fast-acting headache relief, and Dale Earnhardt Jr., the driver known for his speed on and off the NASCAR track, are joining forces for a nationwide search to find Dale Jr.’s fastest fan.
Sign-up for Dale Earnhardt Jr. and Goody’s® Headache Relief Shot® Search for the Fastest Fan investment picks
Company to have strong presence at TCT 2013 with new iFR/FFR data from ADVISE II and analysis of IVUS use in ADAPT-DES featured in scientific program SAN DIEGO , Oct.
Sign-up for Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013 investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Expect a heightened focus on revenue and corporate capital expenditure spending as earnings season reaches its midpoint this week.
Sign-up for MARKET SNAPSHOT: Earnings Season Focus Shifts To Revenue, Capex investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Expect a heightened focus on revenue and corporate capital expenditure spending as earnings season reaches its midpoint this week.
Sign-up for UPDATE: Earnings season focus shifts to revenue, capex investment picks
New store design focuses on customer experience TROY, Mich.
Sign-up for AT&T Opens New Store In Troy Featuring An Innovative Design That Mirrors Customers' Mobile Lifestyle investment picks
2013/10/27
Twitter has surpassed Facebook as the most popular social networking site among teens in the U.S., according to a study released in October by Piper Jaffray, a financial firm.
Sign-up for UPDATE: 10 things Twitter won't tweet -2- investment picks
2013/10/27
By AnnaMaria Andriotis 1.
Sign-up for UPDATE: 10 things Twitter won't tweet investment picks
Medgenics, Inc. (NYSE MKT:MDGN and AIM:MEDU, MEDG) , developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that new, positive data on the Company’s second-generation viral vectors were highlighted in a poster presentation at the European Society of Gene and Cell Therapy Congress.
Sign-up for Medgenics Reports Positive Data with Second-Generation Viral Vectors at European Society of Gene and Cell Therapy Congress investment picks
2013/10/27
BEIJING--China Construction Bank Corp.'s (0939.HK) third-quarter net profit rose 9.4% on year thanks to higher interest income and commissions, the bank said on Sunday.
Sign-up for China Construction Bank 3Q Net Profit up 9.4% on Year at CNY56.8 Billion investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Apple Inc. is likely to dominate corporate news on Monday as it reports its fiscal fourth-quarter results, which while not a blowout are expected to show steady demand for its flagship iPhone.
Sign-up for UPDATE: Apple is Monday's stock to watch as results loom investment picks
Shows to maximize trade opportunities for international buyers sourcing hot fashion products HONG KONG , Oct.
Sign-up for Global Sources' China Sourcing Fairs fashion shows open with 1,300 booths investment picks
COSTA MESA, Calif., Oct.
Sign-up for T3 Motion Prepares to Launch New National Fleet Services Maintenance Program investment picks
2013/10/31
NEW YORK (MarketWatch) -- American International Group Inc. (AIG) said Thursday its third-quarter insurance operating income was up 38% to $2.2 billion, compared to $1.61 billion a year earlier.
Sign-up for AIG shares fall 3% on third quarter results investment picks
2013/10/30
By Tess Stynes Exelon Corp.'s (EXC) third-quarter earnings surged as the nuclear-power producer benefited from positive hedging impacts and lower costs.
Sign-up for Exelon 3rd-Quarter Profit Soars on Positive Hedging Impacts, Lower Costs investment picks
Facebook Inc.'s (FB) revival continued Wednesday as its surging mobile-advertising business helped the social network post a third-quarter profit, making its bumpy initial public offering last year seem like a distant memory.
Sign-up for Facebook Swings to Profit on Mobile Growth investment picks
2013/11/2
By Sital S.
Sign-up for Air travel delays continue in wake of LAX shooting investment picks
2013/11/2
NEW HAVEN, Conn., Nov.
Sign-up for Achillion's Uridine-Analog Nucleotide Prodrug, ACH-3422, Shows Compelling Preclinical Profile investment picks
2013/11/2
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two Phase 2 studies evaluating an all-oral treatment regimen of the investigational once-daily nucleotide analogue sofosbuvir plus ribavirin (RBV) for both the prevention and treatment of recurrent chronic hepatitis C virus (HCV) infection among patients who undergo liver transplantation.
Sign-up for Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection among patients co-infected with HIV.
Sign-up for Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from two studies, the Phase 3 VALENCE study and the Phase 2 LONESTAR-2 study, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection among patients infected with genotype 3 HCV.
Sign-up for Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients investment picks
2013/11/2
Normal levels of apoptosis and caspase activity in healthy volunteers are not reduced by emricasan SAN DIEGO, Nov.
Sign-up for Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting(R) investment picks
2013/11/2
Bristol-Myers Squibb Company (NYSE: BMY) today announced the submission of a New Drug Application (NDA) to Japan’s Pharmaceutical and Medical Devices Agency seeking the world’s first interferon-free and ribavirin-free treatment regimen for patients with chronic hepatitis C.
Sign-up for BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection investment picks
Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting Canada NewsWire Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 per cent of patients to date in two of the three combination arms studied MONTREAL , Nov.
Sign-up for Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting investment picks
2013/11/2
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, with or without twice-daily ribavirin, administered for 12 weeks to treatment-naïve, non-cirrhotic patients with HCV genotype 1a and 1b infection.
Sign-up for Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting investment picks
2013/11/2
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0907943001&sourceType=1 http://www.ccnmatthews.com/logos/20051006-BMO170.jpg TORONTO, ONTARIO --
Sign-up for REPEAT-BMO Insurance Study: More than Two-thirds of Canadian Women are Concerned about the Financial Costs of Cancer investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: German Econ Min Wants Future Government to Rule on Airbus Loan Payment to REPEAT-BMO Insurance Study: More than Two-thirds of Canadian Women are Concerned about the Financial Costs of Cancer
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity